Experimental Immunotherapy Shows High Response Rate in Advanced Lung Cancer
Lombardi Comprehensive Cancer Center at Georgetown UniversityAn early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO) May 29-June 2 in Chicago.
RSS